Jmk1979
Posted - 1 hour ago
I'll take my chances in stead of follow this fraud $SAVA https://en.m.wikipedia.org/wiki/Martin_Shkreli
MITKInvestor
Posted - 1 hour ago
$SAVA Shorting 10k shares here based on Martin Shkreli's financial advice
BWUSAF
Posted - 1 hour ago
@kean626 - Seen $atom or $sava charts (daily... weekly)... tick-tock
89129king
Posted - 3 hours ago
$SAVA Sell before it's too late
RingoZingo
Posted - 4 hours ago
$SAVA Straight out of the Cassava Science Cancer Patent, attached preclinical studies using standard mouse cancer models showing survival Kaplan Meir curves and tumor volume reduction curves in comparison to Gemcitabine a standard chemo drug. Combine this data with the university of Milan data in pituitary tumors….It‘s just a matter of time until simufilam is used in cancer either as a mono therapy or in combination per my appended post below! Phase 3 Rethink in Alzheimer’s reads out by EOY! 🥳
TwittStoxx
Posted - 4 hours ago
$SAVA Is earnings out next Tuesday - 11/5 ?
Terramin
Posted - 4 hours ago
$SAVA If the RETHINK trial is positive, hopefully we can get a big name journalist to do an expose. the shady side of biotech and all the bad actors need to get exposed
Braveheart_13
Posted - 5 hours ago
$SAVA FDA has likely not halted clinical trials because the company is so close to a readout and can dig its own grave with obscure data. FDA intervening may come off as a political move to the conspiracy theorists so they have nothing to lose by waiting and letting the house of cards fall
Wellthen
Posted - 5 hours ago
$SAVA Some desperate ramblings over on the YMB about naloxone and simufilam doing the same thing. Close, but very different. Explains a few things.
Keroman
Posted - 6 hours ago
$SAVA Did a high schooler post this? LOL
Wellthen
Posted - 6 hours ago
$SAVA @fitoto $1.4B spent on an already discredited pre-clinical amyloid approach and technology. Should SAVA ph3 prove out, I see $100B.
Twits_Ghost
Posted - 6 hours ago
$SAVA In your fucking dreams pal!
fitoto
Posted - 6 hours ago
$SAVA Still dream?
Abbvie spent $1.4B in cash purchased an Alzheimer’s drug just got into phase 1 stage. No one wants buy SAVA despite its drug is in phase 3. Why? Because SAVA is a scam.
Twits_Ghost
Posted - 7 hours ago
$SAVA Fuck all the nazis on this board
mon3y_nt_easy
Posted - 7 hours ago
$SAVA
89129king
Posted - 7 hours ago
$SAVA Generational short opportunity
ProblemEliminator
Posted - 8 hours ago
$SAVA
big_cat777
Posted - 8 hours ago
$SAVA Teaser or leaker, either way is fine by me.
zimzimrs
Posted - 10 hours ago
$SAVA VRTIX - Vanguard Russell 2000 Index Fund Institutional Shares reports 8.63% increase in ownership of SAVA / Cassava Sciences, Inc. On October 28, 2024 - VRTIX - Vanguard Russell 2000 Index Fund Institutional Shares filed a NPORT-P form disclosing ownership of 164,681 shares of Cassava Sciences, Inc. (US:SAVA) valued at $4,727,992 USD
DDLearning
Posted - 10 hours ago
$SAVA the Last two CTADS gave a pump to SAVA because big time Institutional buys… Buckle long and strong SAVA investors…it’s not a question of what, it is a question of when? Patience is the key…Hold your positions because payday and healing is coming to us and the patients…
TwittStoxx
Posted - 10 hours ago
$SAVA Buy buy buy!!!
89129king
Posted - 10 hours ago
$SAVA Going much lower
89129king
Posted - 10 hours ago
$SAVA Sell sell sell
MarcoFla99
Posted - 10 hours ago
$SAVA FYI: Nice read from Reddit Irrefutable facts Here are irrefutable and important facts to remind ourselves: SAVA shorts don’t know more about clinical fraud than the FDA. The FDA is the gate keeper and the ultimate decider in the matter. And so, the FDA has firmly decided to ignore the hoopla about the western blots innuendos and hastily retracted scientific papers; the cabale in the CP, other petitions, and the media to stop P3; and even follow federal agencies’ investigations, indictments and financial changes against Cassava. Instead, the FDA has quietly decided to let Cassava complete the P3 it has green-lighted, having agreed then in SPAs that its approval of the P3’s design, together with positive endpoints will be sufficient for NDA approval. It so happens that the endpoints are about to be revealed in a few weeks. SAVA shorts are parasites, as they need to suck on weak longs’ blood to thrive, to impoverish them in order to enrich themselves.
MarcoFla99
Posted - 10 hours ago
$SAVA FYI: More, just out of greed, they would be happy to destroy the company, not caring that Cassava might actually have an effective AD drug. Yes, longs gain when these heartless shorts are squeezed dry. But basically, SAVA longs want to hold to their shares, they care that Cassava finds an effective drug to benefit the AD community, and they hope that Cassava will grow, or get bought out dearly, to enrich itself and its shareholders. So, at their cores, SAVA longs play the win-win and growth game, while SAVA shorts play the zero-sum and total annihilation game. Much remains at stake for the AD community, as well as the FDA, because the much touted breakthrough, miracle MAB drugs are not really such, as they are struggling to take off at home and remain grounded elsewhere (in the EU, the UK, and Australia). Giving these irrefutable facts and the highly anticipated P3 results now just a few weeks away, no long-time invested Sava long in their right mind would sell shares at this time.
zimzimrs
Posted - 10 hours ago
$SAVA One day closer to possibly the biggest blockbuster drug approval of all time
StockMama23
Posted - 10 hours ago
$SAVA The $SAVA shorts next line of attack is to try to attack $SAVA's patents. This is what Martin scumbag posted today.
satrasal
Posted - 10 hours ago
$sava pps is 10% down from oct 22nd. But dec 20 45 calls are up 25%. Same with Jan calls. Oct 11 pps of approx 25 was the last day calls were cheap.
Bob_C
Posted - 11 hours ago
$SAVA Does anyone else see this timeline differently? 1. Sometime before EOY, probably before Dec 20th, P3 Rethink Topline data Released. 2. Either at the same time or shortly after Biomarker data from 100/800 Rethink patients 3. Remember the announcement on the Call that Cassava has contracted at least one outside lab to run confirmatory trial... Is this going to come out between the two P3's... 4. Some BP offers - After Rethink and Before Refocus, so before Mid 2025 (The Sooner the Better, BUT AFTER the Rethink Data!) 5. Confirmatory Data from the Rethink Patients in the P3 OLE, AFTER the IRB approves the changes to that trial and allows Cognitive and Biomarker testing. Then Cassava has data for patients ON the drug for up to 2.5 years and additional data from Former Placebo patients that likely declined and REBOUNDED once on the drug! NDA - Depending on how good the Rethink data is, this could be announced Jan, Feb, March (maybe after the confirmatory results from the Rethink P3 OLE